Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial

By sjmartinez • August 22, 2024

Armstrong AW, Gooderham M, Lynde C, Maari C, Forman S, Green L, Laquer V, Zhang X, Franchimont N, Gangolli EA, Blau J, Zhao Y, Zhang W, Srivastava B, Heap G, Papp K. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Aug 21:e242701. doi: 10.1001/jamadermatol.2024.2701. Epub ahead of print. PMID: 39167366; PMCID: PMC11339701.

Tags: Dermatology, Publications

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]

Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma

Dong E, Yashar S, Mandelkern M, Kaunitz J. Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma. Dig Dis Sci. 2024 Dec 11. doi: 10.1007/s10620-024-08775-1. Epub[...]